

# CA PALBO 125

(Palbociclib 125 mg Caps)



## Breast Cancer

The first CDK4/6 inhibitor to be approved for treatment of **HR-positive and HER2-negative**

locally advanced or metastatic breast cancer. Used in combination therapy with either letrozole or fulvestrant.

**The selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.**

CA Palbo 125 mg PO qDay for Days 1-21 of each 28-day cycle along with Aromatase Inhibitor.

**Combination therapy with fulvestrant**

### **Dosage:**

CA PALBO 125 mg PO qDay for Days 1-21 of each 28-day cycle

Fulvestrant 500 mg IM on Days 1, 15, and 29, and then once monthly thereafter



112,113,114 Crescent Business Park,  
Sakinaka Telephone exchange Lane.  
Andheri (East). Mumbai 400 072



[www.mxmhealthcare.com](http://www.mxmhealthcare.com)

[assist@mxmhealthcare.com](mailto:assist@mxmhealthcare.com)

+91 22 4801 6166 / +91 22 4616 6610